Posted On: 03/26/2015 12:02:08 PM
Post# of 30066
Re: biotechexpert #18880
Quote From the blog.
An important reason for pushing the timeline for the up-listing back from the second half of 2014 was the unique opportunity that presented itself to acquire ESS-W, which came with several risks that we successfully navigated, including the dismissal of the litigation previously encumbering the asset which has paved the way for the acquisition to take place. We will now return to immediately focusing on the NASDAQ listing to position the company for an appreciation in value.
Sorry Biotech, I did not mean to say that the ESS deal was completely finished. My post was on the focus returning to uplisting. I went ahead and pasted it so you can work on your reading comprehension.
WD
An important reason for pushing the timeline for the up-listing back from the second half of 2014 was the unique opportunity that presented itself to acquire ESS-W, which came with several risks that we successfully navigated, including the dismissal of the litigation previously encumbering the asset which has paved the way for the acquisition to take place. We will now return to immediately focusing on the NASDAQ listing to position the company for an appreciation in value.
Sorry Biotech, I did not mean to say that the ESS deal was completely finished. My post was on the focus returning to uplisting. I went ahead and pasted it so you can work on your reading comprehension.
WD
(0)
(0)
